MAZAL PLANT geht da noch was ? - 500 Beiträge pro Seite

[onkelen]

QUELLE: Mazal Anlage Pharmaceuticals Inc.
21. Mai 2008 14:27 UND
Mazal Betriebspharmazeutische produkte verkündet Ernennung neuen CEOs und des neuen Unternehmensberaters
Hervorgehobene Verbindungen


MacReport.Net

NEW YORK, NY--(Marketwire - 21. Mai 2008) - Mazal Anlage Pharmaceuticals Inc. (PINKSHEETS: MZPP) (FRANKFURT: M9J) („Mazal“) verkündet, dass Eliyahu BenTal Tolchinsky als Direktor und Generaldirektor der Firma ernannt worden ist.

Herr Tolchinsky, ein Absolvent der Universität von Cornell und Tulane der juristischen Fakultät, hat einen starken Hintergrund in der Forschung und Entwicklung, im Schutz des geistigen Eigentums und in der regelnden Befolgung. Herr Tolchinsky ist durch die Patentabteilung von Webb beschäftigt worden u. verbindet in Rechovot, Israel, die R&D-Abteilung von Mazal Pharmaceuticals, Inc., Hadassah Ein Kerem Krankenhaus, Jerusalem, Israel, R.A.M. Technologien, Jerusalem, Israel und Halsey Gruppen-Berater in New-Jersey.

Herr Tolchinsky angegeben, „ich freue mich, die Firma zum folgenden Stadium der Entwicklung zu holen.“

Mazals neuer Unternehmensberater ist Stephen M. Fleming, Rechtsanwaltsbüros von Stephen M. Fleming PLLC, 110 Wall Street, 11. Stock, New York, New York 10005, Telefon [phone].

Über Mazal Anlage Pharmaceuticals Inc.

Mazal Plant Pharmaceuticals, Inc. ist eine Frühstadium pharmazeutische Vollpflanzenverwertungsgesellschaft, deren Auftrag, Behandlungen für chronische Krankheiten von den Kombinationen der vollständigen Anlagen zu entwickeln und Aktionärwert durch verhandelte Verhältnisse zu den strategischen Partnern zur Kapitalskommerzialisierung und zum Marketing dieser Behandlungen auf einer allein stehenden oder Kombinationsbasis aufzubauen ist.

Mazal Betriebspharmazeutische produkte ist genehmigt worden, um ein großräumiges zu leiten, double-blind, die Studie mit 4 Armen in den menschlichen Themen, die mit alphalipoproteinemia bestimmt werden (Themen mit niedrigem HDL). Die Themen werden entweder MAHDL, Placebo, Statin + Placebo oder MAHDL + Statin für 4 Monate gegeben und auf Änderungen in HDL, in LDL, im Cholesterin, in den Triglyzeriden und in den CRP Serumniveaus geprüft.

Zusätzliche Information über Mazal Plant Pharmaceuticals, Inc. kann an gefunden werden: http://www.mazalpharmaceutical.com.

Vorausschauende Aussagen

„Sicher-Hafen“ Aussage unter der privaten Sicherheits-Rechtsstreit-Verbesserung-Tat von 1995 dieses Pressekommuniqué enthält vorausschauende Informationen im Sinn von Abschnitt 21E des Börsengesetzes von 1934, einschließlich Aussagen betreffend alle möglichen Verkäufe der Produkte, sowie Aussagen, die die Wörter „umfassen,“ „erwartet,“ „vorwegnimmt,“ oder ähnliche Ausdrücke glaubt. Solche vorausschauenden Aussagen beziehen die bekannten und unbekannten Risiken, die Ungewissheiten und andere Faktoren, die die tatsächlichen Resultate, die Leistung oder die Ausführungen Mazal Anlage Pharmaceuticals Inc. verursachen können, um sich von denen materiell zu unterscheiden mit ein, die durch solche vorausschauenden Aussagen angedeutet werden oder ausgedrückt sind. Solche Faktoren umfassen unter anderem die Risikofaktoren, die in den folgenden Reports der Mazal Betriebspharmazeutischen produkte Inc. eingeschlossen sind, die mit der Börsenaufsichtsbehörde unter der Austausch-Tat vorgelegt werden. Dieses Pressekommuniqué spricht ab dem Datum, das zuerst oben festgelegt wird und Mazal Betriebspharmazeutische produkte übernimmt keine Verantwortlichkeit, die Informationen zu aktualisieren, die hierin für die Ereignisse eingeschlossen sind, die hiervon nach dem Datum auftreten.

[onkelen]

ende 2006

Das New Yorker Biotechunternehmen Mazal Plant Pharmaceuticals wurde im Jahr 2005 gegründet. Der Firmensitz befindet sich im Schatten des Empire State Buildings direkt in Manhattan. Das vielversprechende Unternehmen entstand aus dem Zusammenschluss mehrerer Vorgängergesellschaften, die sich in die jetzige Firma eingebracht haben. Namentlich waren dies: Akid Corporation, Advanced Plant Pharmaceuticals und Delaware Mazal. Eine Besonderheit bei Mazal Plant ist es, dass sich das Unternehme auf die Erforschung von Medikamenten “auf Pflanzenbasis” konzentriert. Im Unternehmen verfolgt man den Ansatz, die Pflanze als Ganzes zu sehen und aus ihr wichtige Essenzen zum Nutzen des Menschen zu gewinnen. Mazal ist noch in einem frühen Stadion der Entwicklung, hat aber schon erstaunliche Forschungsergebnisse erzielt. Dies macht das Unternehmen für Anleger interessant und regt zudem Übernahmephantasien an.

Einen Schwerpunkt der Arbeit legt man bei Mazal Plant Pharmaceuticals auf Behandlungsmethoden für chronische Krankheiten. Dabei untersucht man Kombinationen verschiedener Pflanzenwirkstoffe. Drei Untersuchungsgebiete sind für das Unternehmen dabei von besonderem Interesse: erhöhte Cholesterinwerte, Leukämie und Alzheimer.

Am weitesten fortgeschritten ist das Unternehmen bei der Forschung nach wirksamen Cholesterinmitteln. Der Markt für Cholesterin senkende Medikamente ist riesig. Die Umsätze in diesem Bereich liegen weltweit jährlich bei etwa 23 Milliarden Dollar. Den Großteil dieses Umsatzes teilen sich rund ein Dutzend Medikamente. Ein wirksames Medikament auf Pflanzenbasis hätte hier absolutes Blockbuster-Potential (Jahresumsatz über 1 Milliarde USD).


FAZIT:

Spekulativen Anlegern bietet Mazal Plant Pharmaceuticals eine spannende und chancenreiche Investmentgelegenheit. Die Marktkapitalisierung von Mazal beträgt derzeit ungefähr 22 Millionen USD. Biotechunternehmen mit Aussicht auf ein Blockbuster-Medikament werden üblicherweise mit einer Marktkapitalisierung von über 100 Millionen USD bewertet. Spätestens nach der erfolgreich durchgeführten Phase II Studie wäre diese Höherbewertung auch für Mazal gerechtfertigt. Anleger, die sich der dennoch hohen Risiken bewusst sind, können die Aktie spesengünstig in Frankfurt ordern. Aufgrund der relativ geringen Umsätze sollten Orders streng limitiert werden. Achtung: Stoppkurse setzen!

[onkelen]

Mazal Plant Pharmaceuticals Announces Appointment of Dr. Michael Silver as New Scientific Director


NEW YORK, NY--(Marketwire - May 29, 2008) - Mazal Plant Pharmaceuticals Inc. (PINKSHEETS: MZPP) (FRANKFURT: M9J) announced the appointment of Dr. Michael Silver as the company's new Scientific Director.

Dr. Silver has over 15 years of experience in the biotechnology, pharmaceutical and medical device industries serving as Director of Business Development and Senior Scientist at Bio-Imaging Technologies, Inc., as Director of Scientific Services at Synarc, Inc. and as Vice President, Clinical Research at DOBI Medical International, Inc., in charge of the development of their breast cancer diagnostics device. Dr. Silver has eight years' experience implementing imaging biomarkers in clinical trials for oncology, central nervous system (CNS), rheumatology, and cardiovascular therapeutics. He received his Bachelor of Science degree in Physics with honors from Lafayette College. His Master's in Biophysics and his Ph.D. in Electrical Engineering and Computer Science were earned at Johns Hopkins University. Dr. Silver has co-authored over 40 peer-reviewed publications and presentations, and is currently a Research Assistant Professor (part-time) of Psychiatry at NYU Medical School.

Mr. Eliyahu Tolchinsky, Mazal's CEO, said, "We are continuing to focus on creating a strong bio-tech, pharmaceutical management team to ensure the company's success in developing our HDL cholesterol drug."

About Mazal Plant Pharmaceuticals Inc.

Mazal Plant Pharmaceuticals, Inc. is an early-stage whole plant pharmaceutical development company whose mission is to develop treatments for chronic diseases from combinations of whole plants and to build shareholder value through negotiated relationships with strategic partners to fund commercialization and marketing of these treatments on a stand-alone or combination basis.

Mazal Plant Pharmaceuticals has been approved to conduct a large-scale, double-blind, 4-arm study in human subjects diagnosed with alphalipoproteinemia (subjects with low HDL). The subjects will be given either MAHDL, placebo, Statin + Placebo or MAHDL+ Statin for 4 months and tested for changes in HDL, LDL, Cholesterol, Triglycerides and CRP serum levels.

Additional information on Mazal Plant Pharmaceuticals, Inc. may be found at: http://www.mazalpharmaceutical.com.

Forward-Looking Statements

"Safe-Harbor'' Statement Under the Private Securities Litigation Reform Act of 1995 This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, including statements regarding any potential sales of products as well as statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements Mazal Plant Pharmaceuticals Inc., to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in Mazal Plant Pharmaceuticals Inc.'s subsequent reports filed with the Securities and Exchange Commission under the Exchange Act. This press release speaks as of the date first set forth above and Mazal Plant Pharmaceuticals assumes no responsibility to update the information included herein for events occurring after the date hereof.

[onkelen]

5-May-2008

Change in Directors or Principal Officers


Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

In April, 2008, shareholders of Mazal Pharmaceuticals, Inc. (the "Company") holding a majority of the outstanding shares of the Company (the "Majority Shareholders") voted to remove Simcha Edell and Mechael Kanovsky as directors of the Company. Further, the Majority Shareholders also appoint Eliyahu Tolchinsky as the sole director. Mr. Tolchinsky, as the sole director of the Company, terminated all executive officers of the Company including Simcha Edell and Mechael Kanovsky. Mr. Tolchinsky was also appointed as the Chief Executive Officer, Chief Financial Officer, and Secretary of the Company.

Mr. Tolchinsky, since 2007, has been employed by Webb & Associates in Rechovot, Israel ,with their patent deparment. From 2006 through 2007, Mr. Tolchinsky served as an editor for Hadassah Ein Kerem Hospital, Jerusalem, Israel, as an attorney for R.A.M. Technologies, Jerusalem, Israel in their patent department, 2006-2007and in the regulatory department for Amazon Biotech, Inc. During 2005, Mr. Tolchinsky served in the grants department for Halsey Group and from 2004 through 2005, Mr. Tolchinsky served in the grants department of Freemind Consultants in Jerusalem, Israel. Mr. Tolchinsky received his BA from Cornell University in 1989 and his JD from Tulane University in 1992.

[onkelen]

14-May-2008

Other Events


Item 8.01. Other Events.

On May 1, 2008, the Board of Directors of the Registrant adopted a resolution setting forth the rights, preferences, powers, privileges and limitations of the Registrant's Preferred Stock. In addition, on May 1, 2008, The Board of Directors further authorized the issuance of 12,000 shares of Preferred Stock to creditors of the Registrant.

Immediately following the adoption of these resolutions, the management of the Registrant commenced the process of updating its registered agent information with the State of Nevada and of filing a Certificate of Designation relating to the Preferred Stock with the State of Nevada.

However, unbeknownst to the management of the Registrant, on May 5, 2008, a Form 8-K was filed without the knowledge or authorization of the management of the Registrant reporting on a purported change in the management of the Registrant by means of a written consent adopted by the holders of a majority of the outstanding shares of the Registrant in April 2008.

The Board of Directors of the Registrant adopted the May 1, 2008 resolutions described in this Form 8-K prior to having any knowledge of the May 5, 2008 Form 8-K filed by the purported new management. Moreover, a Rule 14C Information Statement was neither filed with the SEC nor distributed to the shareholders of the Company. As such, the purported action taken by the written consent described in the May 5, 2008 Form 8-K is of no effect. The purported change is also invalid under applicable state law. Thus, management retains its authority to act on behalf of the Registrant.

Management was delayed in filing this Form 8-K because of a refusal by the Registrant's printer to provide services to the Registrant after having been contacted by counsel to the purported new management.

The rights, preferences, powers, privileges and restrictions, qualifications and limitations of the Preferred Stock are as follows:

1. Dissolution, Liquidation or Winding Up: The holders of the Preferred Stock shall receive assets and surplus funds available for distribution to stockholders upon any liquidation, whether voluntary or involuntary, in the amount of the Debt prior to the distribution to the other stockholders.

2. Protective Provisions: The consent of the holders of at least 60% of the then-outstanding shares of Preferred Stock shall be required for: (i) any amendment, alteration or repeal of any provision of the Articles of Incorporation or Bylaws of the Corporation; (ii) the issuance of any dividend by the Corporation; (iii) the appointment or removal of any member of the Board of Directors; (iv) any liquidation of the business and affairs of the Corporation or any of its subsidiaries or any change of control transaction involving any of the foregoing entities; or (v) the authorization or issuance of any equity securities (or securities convertible into or exercisable or exchangeable for equity securities) which rank senior or on parity with the Preferred Stock.

3. Redemption: In the event that the Corporation has legally available funds to repay the Debt (the "Funds"), then both the Corporation and the holders of a majority of the shares of Preferred Stock (the "Majority Holders") shall have the right to demand prompt redemption of all of the Preferred Stock.

(a) No later than the second business day after the funds are available, the Corporation shall deliver a written notice to each holder of Preferred Stock to notify each of them of the availability of the Funds (the "Written Notice");

(b) For a period of not longer than sixty (60) days from the date the Written Notice is delivered, the Funds shall be earmarked for repayment of the Debt and the Corporation shall not use the Funds for any other purpose.

(c) Each of the Corporation and the Majority Holders, by written notice to the Corporation and to all of the holders of shares of Preferred Stock, shall have the option to require the redemption of the Preferred Stock by the Corporation within such sixty-day period, such that the Corporation shall make full repayment of the Debt and all of the Preferred Stock shall be cancelled.

On May 8, 2008, the Registrant filed a Certificate of Designation with the State of Nevada.

[onkelen]

NEW YORK, NY--(Marketwire - June 12, 2008) - Mazal Plant Pharmaceuticals Inc. (PINKSHEETS: MZPP) (FRANKFURT: M9J) announced the filing of a provisional patent for its Cholesterol/HDL Investigatonal New Drug formulation. Mazal has already been issued a patent covering its original, first generation formula.

Eliyahu Tolchinsky, Mazal's CEO, said, "Building the company's intellectual portfolio is an important part of building Mazal Plant Pharmaceuticals Inc. in tandem with pending clinical trials."

About Mazal Plant Pharmaceuticals, Inc.

Mazal Plant Pharmaceuticals, Inc. is an early-stage whole plant pharmaceutical development company whose mission is to develop treatments for chronic diseases from combinations of whole plants and to build shareholder value through negotiated relationships with strategic partners to fund commercialization and marketing of these treatments on a stand-alone or combination basis.

Mazal Plant Pharmaceuticals has been approved to conduct a large-scale, double-blind, 4-arm study in human subjects diagnosed with alphalipoproteinemia (subjects with low HDL). The subjects will be given either MAHDL, placebo, Statin + Placebo or MAHDL + Statin for 4 months and tested for changes in HDL, LDL, Cholesterol, Triglycerides and CRP serum levels.

Additional information on Mazal Plant Pharmaceuticals, Inc. may be found at: http://www.mazalpharmaceutical.com.

Forward-Looking Statements

"Safe-Harbor" Statement Under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, including statements regarding any potential sales of products as well as statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Mazal Plant Pharmaceuticals Inc., to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in Mazal Plant Pharmaceuticals Inc.'s subsequent reports filed with the Securities and Exchange Commission under the Exchange Act. This press release speaks as of the date first set forth above and Mazal Plant Pharmaceuticals assumes no responsibility to update the information included herein for events occurring after the date hereof.

[onkelen]

MAZAL PLANT PHARMA
(Other OTC: MZPP.PK)
Last Trade: 0.10
Trade Time: Jun 12
Change: Up 0.01 (11.11%)
Prev Close: 0.09
Open: 0.10
Bid: N/A
Ask: N/A
1y Target Est: N/A
Day's Range: 0.10 - 0.10
52wk Range: N/A
Volume: 10,000
Avg Vol (3m): N/A
Market Cap: N/A
P/E (ttm): N/A
EPS (ttm): N/A
Div & Yield: N/A (N/A)

[onkelen]

Frankfurt 0,05 EUR +0,04 +400,00% 16.06.

[mumuprinz]

Da geht nichts. Abzocke.

Schaut euch mal Amazon Biotech an. Da sitzen die gleichen Leute wie bei Mazal Plant...Silver, Tolchinsky, Edell usw...

Hab selber noch ein paar Amazon Biotech Aktien aber das stinkt gewaltig...

[mumuprinz]

3:50 PM 5/29/08 Mazal Plant Pharmaceuticals Announces Appointment of Dr. Michael Silver as New Scientific Director - Market Wire


2:28 PM 5/21/08 Mazal Plant Pharmaceuticals Announces Appointment of New CEO and New Corporate Counsel - Market Wire


Die selben News, aber Wort für Wort, kam auch am selben Datum für Amazon Biotech raus.